search
Back to results

Heart Rate Reduction in Heart Failure (CARVIVA-HF)

Primary Purpose

Heart Failure

Status
Completed
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
ivabradine
"Drug:Carvedilol" and "Drug:Ivabradine"
Carvedilol
Sponsored by
IRCCS San Raffaele
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring heart failure, heart rate, ivabradine, carvedilol

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • heart failure II-III
  • ischemic origin
  • stable medications from at least 3 months
  • > 3 months from an acute ischemic syndrome or revascularization procedure
  • naive on heart rate reducing agents

Exclusion Criteria:

  • bradycardia
  • hypersensitivity or contraindications to study drugs
  • exercise tolerance at 6 minute walking test <100 m or >400 m

Sites / Locations

  • Centre for Clinical and Basic Research - IRCCS San Raffaele
  • IRCCS San Raffaele

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Experimental

Arm Label

Ivabradine

Carvedilol

"Drug:Carvedilol" and "Drug:Ivabradine"

Arm Description

7.5 mg bd

up to 25 mg bd

up to 12.5/5 mg bd

Outcomes

Primary Outcome Measures

Exercise Tolerance Assessed by 6 Minute Walking Test
Distance measured at 6 minute walking test. The 6 minute walking test was performed according to standardised procedure at baseline, before inclusion (at least 1 week after baseline evaluation), and at the end of the study. Patients who had not done at least two tests in the past underwent two practice 6 minute walking tests at least 3 days apart. Results are expressed in terms of distance walked (metres). The test was supervised by a physical therapist. Patients were asked to walk at their own maximal pace a 100 m long hospital corridor. At the beginning of the last (6th) minute of the test a standard phrase of encouragement was told. Patients were allowed to stop if signs or symptoms of significant distress occurred (dyspnea, angina), through they were instructed to resume walking as soon as possible.
Maximal Oxygen Consumption
Functional capacity was assessed by means of a cardiopulmonary exercise test with a bicycle ergometer with gas exchange monitoring (Vmax 29 C, SensorMedics). Peak oxygen consumption was defined as the maximal oxygen consumption (MVO2) observed during exercise.

Secondary Outcome Measures

Quality of Life
Quality of life (QoL) was evaluated using the Visual Analogue Scale (VAS) which is a global measurement of QoL, allowing a subjective assessment of the impact of the disease and treatment. Patients are asked to indicate their current state in a line from 0 (worst state) to 10 (best state), with higher values therefore representing a better outcome.
New York Heart Association (NYHA) Class
The 1994 NYHA Classification system is a measure of functional status. It was designed for clinical assessment of patients by physicians as NYHA class I, II, III, or IV, on the basis of patient's limitations in physical activities caused by cardiac symptoms. Class I describes patients with cardiovascular disease (CVD) but without resulting limitation of physical activity. There is no objective evidence of CVD. Class II describes patients with CVD resulting in slight limitation of physical activity. There is objective evidence of minimal CVD. Class III describes patients with CVD resulting in marked limitation of physical activity. There is objective evidence of moderately severe CVD. Class IV describes patients with CVD resulting in inability to carry on any physical activity without discomfort. There is objective evidence of severe CVD. Here we report data on number of patients showing an improvement by at least one NYHA class according to treatment allocation.

Full Information

First Posted
April 19, 2010
Last Updated
September 29, 2014
Sponsor
IRCCS San Raffaele
search

1. Study Identification

Unique Protocol Identification Number
NCT01178528
Brief Title
Heart Rate Reduction in Heart Failure
Acronym
CARVIVA-HF
Official Title
Effect of Ivabradine, Carvedilol or Their Combination in Patients With Heart Failure
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS San Raffaele

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients with heart failure (HF) have a limited exercise tolerance,few pharmacological interventions have been proven effective in improving exercise capacity. At the presence there i conflicting evidence on the effectiveness of beta-blockers on exercise capacity. Ivabradine has been shown to improve prognosis in patients with ischemic heart disease, left ventricular dysfunction and heart rate > 70 bpm. The association of ivabradine and atenolol has been proven effective in increasing exercise tolerance in patients with ischemic heart disease. Aim of the present study is to evaluate the effect of heart rate reduction with ivabradine, carvedilol or their combination in patients with heart failure of ischemic origin.
Detailed Description
Patients with chronic heart failure of ischemic origin (120) Stable coronary artery disease Acute coronary syndromes > 3 months Revascularization procedures > 3 months Naive on heart rate reducing agents New York Heart Association (NYHA) Class II III 6 minute walking test (6MW) tolerance between 200 and 400 m Stable medications for the past 3 months Treatment Ivabradine up to 7.5 mg b.i.d. Carvedilol up to 25 mg b.i.d. Carvedilol and Ivabradine up to 12.5/5 mg b.i.d. Efficacy measure Intention to treat Exercise tolerance Quality of life

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
heart failure, heart rate, ivabradine, carvedilol

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
121 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ivabradine
Arm Type
Experimental
Arm Description
7.5 mg bd
Arm Title
Carvedilol
Arm Type
Active Comparator
Arm Description
up to 25 mg bd
Arm Title
"Drug:Carvedilol" and "Drug:Ivabradine"
Arm Type
Experimental
Arm Description
up to 12.5/5 mg bd
Intervention Type
Drug
Intervention Name(s)
ivabradine
Intervention Description
7.5 mg bd
Intervention Type
Drug
Intervention Name(s)
"Drug:Carvedilol" and "Drug:Ivabradine"
Intervention Description
up to 12.5/5 mg bd
Intervention Type
Drug
Intervention Name(s)
Carvedilol
Intervention Description
25 mg bd
Primary Outcome Measure Information:
Title
Exercise Tolerance Assessed by 6 Minute Walking Test
Description
Distance measured at 6 minute walking test. The 6 minute walking test was performed according to standardised procedure at baseline, before inclusion (at least 1 week after baseline evaluation), and at the end of the study. Patients who had not done at least two tests in the past underwent two practice 6 minute walking tests at least 3 days apart. Results are expressed in terms of distance walked (metres). The test was supervised by a physical therapist. Patients were asked to walk at their own maximal pace a 100 m long hospital corridor. At the beginning of the last (6th) minute of the test a standard phrase of encouragement was told. Patients were allowed to stop if signs or symptoms of significant distress occurred (dyspnea, angina), through they were instructed to resume walking as soon as possible.
Time Frame
3 months
Title
Maximal Oxygen Consumption
Description
Functional capacity was assessed by means of a cardiopulmonary exercise test with a bicycle ergometer with gas exchange monitoring (Vmax 29 C, SensorMedics). Peak oxygen consumption was defined as the maximal oxygen consumption (MVO2) observed during exercise.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Quality of Life
Description
Quality of life (QoL) was evaluated using the Visual Analogue Scale (VAS) which is a global measurement of QoL, allowing a subjective assessment of the impact of the disease and treatment. Patients are asked to indicate their current state in a line from 0 (worst state) to 10 (best state), with higher values therefore representing a better outcome.
Time Frame
3 months
Title
New York Heart Association (NYHA) Class
Description
The 1994 NYHA Classification system is a measure of functional status. It was designed for clinical assessment of patients by physicians as NYHA class I, II, III, or IV, on the basis of patient's limitations in physical activities caused by cardiac symptoms. Class I describes patients with cardiovascular disease (CVD) but without resulting limitation of physical activity. There is no objective evidence of CVD. Class II describes patients with CVD resulting in slight limitation of physical activity. There is objective evidence of minimal CVD. Class III describes patients with CVD resulting in marked limitation of physical activity. There is objective evidence of moderately severe CVD. Class IV describes patients with CVD resulting in inability to carry on any physical activity without discomfort. There is objective evidence of severe CVD. Here we report data on number of patients showing an improvement by at least one NYHA class according to treatment allocation.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: heart failure II-III ischemic origin stable medications from at least 3 months > 3 months from an acute ischemic syndrome or revascularization procedure naive on heart rate reducing agents Exclusion Criteria: bradycardia hypersensitivity or contraindications to study drugs exercise tolerance at 6 minute walking test <100 m or >400 m
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maurizio Volterrani, MD
Organizational Affiliation
IRCCS San Raffaele
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Giuseppe MC Rosano, MD, PhD
Organizational Affiliation
IRCCS San Raffaele
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Cristiana Vitale, MD, PhD
Organizational Affiliation
IRCCS San Raffaele
Official's Role
Study Director
Facility Information:
Facility Name
Centre for Clinical and Basic Research - IRCCS San Raffaele
City
Roma
ZIP/Postal Code
00100
Country
Italy
Facility Name
IRCCS San Raffaele
City
Roma
ZIP/Postal Code
00100
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
19944362
Citation
Fasullo S, Cannizzaro S, Maringhini G, Ganci F, Giambanco F, Vitale G, Pinto V, Migliore G, Torres D, Sarullo FM, Paterna S, Di Pasquale P. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009 Dec;15(10):856-63. doi: 10.1016/j.cardfail.2009.05.013. Epub 2009 Jul 3.
Results Reference
background
PubMed Identifier
19892778
Citation
Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail. 2010 Jan;12(1):75-81. doi: 10.1093/eurjhf/hfp154. Epub 2009 Nov 5.
Results Reference
background
Links:
URL
http://www.escardio.org
Description
European Society Cardiology guidelines

Learn more about this trial

Heart Rate Reduction in Heart Failure

We'll reach out to this number within 24 hrs